Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL894516 | 0.81 | KDM4E (0.50) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL323522 | 0.81 | KDM4E (0.50) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| Hydrochloric Acid SCHEMBL999646 | 0.79 | KDM4E (0.48) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL190917 | 0.74 | L3MBTL1 (0.45) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL5013 | 0.74 | KDM4E (0.52) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL477197 | 0.74 | KDM4E (0.52) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL5989668 | 0.73 | KDM4E (0.46) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL11058841 | 0.73 | KDM4E (0.46) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL5464811 | 0.73 | KDM4E (0.46) | KMT2AKDM4EMAPTALDH1A1USP2 | |
| SCHEMBL3598094 | 0.73 | KDM4E (0.46) | KMT2AKDM4EMAPTALDH1A1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1871772-B1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE INC (US) | 2014-09-10 | — | — | EP | disclosed |
| US-8044045-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2011-10-25 | — | — | US | disclosed |
| US-8003664-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2011-08-23 | — | — | US | disclosed |
| US-7875629-B2 | minimal side effects, improved selectivity, potency, pharmacokinetics, and/or duration of action; 1-isopropyl-2-oxo-1,2-dihydroquinoline-3-carboxylic acid {(1S,3R,5R)-8-[3-(4-methanesulfonylpiperazine-1-sulfonyl)propyl]-8-azabicyclo[3.2.1]oct-3-yl}amide; reduced motility of the gastrointestinal tract | THERAVANCE, INC. (US) | 2011-01-25 | — | — | US | disclosed |
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2010-11-18 | — | — | US | disclosed |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2010-10-14 | — | — | US | disclosed |
| US-7786136-B2 | Indazole-carboxamide compounds | THERAVANCE, INC. (US) | 2010-08-31 | — | — | US | disclosed |
| EP-1831211-B1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE INC (US) | 2010-06-02 | — | — | EP | disclosed |
| US-7674908-B2 | Indazole-carboxamide compounds as 5-HT4 receptor agonists | THERAVANCE, INC. (US) | 2010-03-09 | — | — | US | disclosed |
| EP-1807422-B1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE INC (US) | 2009-09-02 | — | — | EP | disclosed |
| WO-2006094063-A1 | QUINOLINONE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | THERAVANCE, INC. | 2006-09-07 | — | — | US | disclosed |
| WO-2006069125-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135764-A1 | Indazole-carboxamide compounds | THERAVANCE, INC. | 2006-06-22 | — | — | US | disclosed |
| WO-2006052640-A1 | 5-HT4 RECEPTOR AGONIST COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| WO-2006052889-A2 | QUINOLINONE-CARBOXAMIDE COMPOUNDS | THERAVANCE, INC. (US) | 2006-05-18 | — | — | WO | disclosed |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | THERAVANCE, INC. (US) | 2006-05-11 | — | — | US | disclosed |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | THERAVANCE, INC. | 2006-05-11 | — | — | US | disclosed |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | THERAVANCE BIOPHARMA R&D IP, LLC | 2005-09-08 | — | — | US | disclosed |
| WO-2005080389-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060199839-A1 | Quinolinone compounds as 5-HT4 receptor agonists | HTR4, HTR5A, HTR1A | KMT2A 2124/4885KDM4E 1499/4885MAPT 2978/4885 |
| US-20100292223-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS | HTR4, HTR5A, HTR3B | KMT2A 2426/4885KDM4E 1283/4885MAPT 2189/4885 |
| US-20050197335-A1 | 1-isopropyl-1H-indazole-3-carboxylic acid {(1S,3R,5R)-8-[2-(4-acetylpiperazin-1-yl)-ethyl]8-azabicyclo[3.2.1]oct-3-yl}amide; improved pharmacokinetic, bioavailability; gastrointestinal disorders: irritable bowel syndrome (IBS), chronic constipation, dyspepsia; CNS behavioral, mood disorder | HTR4, HTR5A, HTR3C | KMT2A 2249/4885KDM4E 1798/4885MAPT 2864/4885 |
| US-20060135764-A1 | Indazole-carboxamide compounds | HTR4, HTR5A, HTR3B | KMT2A 2426/4885KDM4E 1283/4885MAPT 2189/4885 |
| US-20060100236-A1 | For therapy of disorder of reduced motility of gastrointestinal tract, chronic constipation, functional dyspepsia, delayed gastric emptying, gastroesophageal reflux disease, gastroparesis, diabetic and iodiopathic gastropathy, post-operative ileus, intestinal pseudo-obstruction, irritable bowel syndrome | GIPR, GPR4, GPR119 | KMT2A 4259/4885KDM4E 3939/4885MAPT 4841/4885 |
| US-20060100426-A1 | Quinolinone-carboxamide compounds | HTR4, HTR5A, HTR2C | KMT2A 1724/4885KDM4E 1306/4885MAPT 2690/4885 |
| US-20100261716-A1 | INDAZOLE-CARBOXAMIDE COMPOUNDS AS 5-HT4 RECEPTOR AGONISTS | HTR4, HTR5A, HTR3B | KMT2A 2306/4885KDM4E 1226/4885MAPT 2525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.